Q3 2016 Earnings Estimate for DexCom Inc. Issued By B. Riley (DXCM)
DexCom Inc. (NASDAQ:DXCM) – Investment analysts at B. Riley issued their Q3 2016 earnings per share (EPS) estimates for shares of DexCom in a note issued to investors on Tuesday. B. Riley analyst G. Chodaczek expects that the brokerage will earn ($0.15) per share for the quarter. B. Riley has a “Neutral” rating and a $97.00 price target on the stock. B. Riley also issued estimates for DexCom’s Q4 2016 earnings at $0.02 EPS, FY2016 earnings at ($0.61) EPS, Q1 2017 earnings at ($0.08) EPS, Q2 2017 earnings at $0.01 EPS, Q3 2017 earnings at $0.07 EPS, Q4 2017 earnings at $0.21 EPS and FY2017 earnings at $0.21 EPS.
A number of other analysts also recently issued reports on DXCM. BTIG Research restated a “buy” rating and set a $92.00 price objective on shares of DexCom in a report on Thursday, August 4th. Canaccord Genuity restated a “buy” rating and set a $95.00 price objective on shares of DexCom in a report on Wednesday, July 13th. Piper Jaffray Cos. restated an “overweight” rating and set a $93.00 price objective on shares of DexCom in a report on Friday, July 15th. JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a report on Monday, June 20th. Finally, Zacks Investment Research downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $95.08.
DexCom (NASDAQ:DXCM) opened at 87.80 on Thursday. DexCom has a 52 week low of $47.92 and a 52 week high of $96.38. The company’s market cap is $7.36 billion. The company has a 50-day moving average of $92.02 and a 200 day moving average of $76.92.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. The company earned $137.30 million during the quarter, compared to the consensus estimate of $132.48 million. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. DexCom’s revenue for the quarter was up 47.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.05) EPS.
In other news, Director Mark G. Foletta sold 1,800 shares of the business’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $94.63, for a total value of $170,334.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terrance H. Gregg sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, August 19th. The stock was sold at an average price of $90.70, for a total transaction of $3,628,000.00. Following the completion of the sale, the insider now owns 451,486 shares of the company’s stock, valued at $40,949,780.20. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the company. Bridger Management LLC purchased a new stake in DexCom during the first quarter worth approximately $56,651,000. State Street Corp raised its stake in DexCom by 7.2% in the first quarter. State Street Corp now owns 1,055,774 shares of the medical device company’s stock worth $71,699,000 after buying an additional 71,009 shares in the last quarter. Renaissance Technologies LLC raised its stake in DexCom by 17.9% in the first quarter. Renaissance Technologies LLC now owns 817,943 shares of the medical device company’s stock worth $55,547,000 after buying an additional 124,000 shares in the last quarter. Calamos Advisors LLC purchased a new stake in DexCom during the second quarter worth approximately $22,764,000. Finally, Geode Capital Management LLC raised its stake in DexCom by 6.3% in the first quarter. Geode Capital Management LLC now owns 523,958 shares of the medical device company’s stock worth $35,581,000 after buying an additional 31,209 shares in the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.